WASHINGTON, Sept. 27 -- University of Minnesota Department of Obstetrics, Gynecology and Women's Health Associate Professor Rahel Nardos submitted a public comment letter to the U.S. Food and Drug Administration (FDA). The writer, a urogynecologist, urged the agency to remove the black box warning on low-dose vaginal estrogen products and to prioritize approval of testosterone therapies for perimenopausal and postmenopausal people. The commenter stated that the current boxed warning on vaginal  more ST